The therapeutic value of these findings is significant, since neprilysin-inhibitors (the peptidase responsible for degrading ANP and BNP, which are ligands for GC-A) are safe and well-tolerated drugs already used for chronic therapy in heart-failure patients (Feygina et al., 2019). Here, NPPA is linked to heart failure.